CINECA IRIS Institutional Research Information System

MATRONE, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.241
AS - Asia 4.154
EU - Europa 3.971
SA - Sud America 734
AF - Africa 325
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 3
Totale 16.439
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.019
SG - Singapore 1.433
CN - Cina 1.182
IT - Italia 1.076
DE - Germania 956
HK - Hong Kong 713
BR - Brasile 607
SE - Svezia 563
GB - Regno Unito 304
AT - Austria 235
VN - Vietnam 227
BG - Bulgaria 219
CI - Costa d'Avorio 163
IN - India 150
CA - Canada 135
RU - Federazione Russa 131
FR - Francia 124
TR - Turchia 111
FI - Finlandia 102
JP - Giappone 74
SN - Senegal 74
PL - Polonia 48
AR - Argentina 47
MX - Messico 47
BD - Bangladesh 37
KR - Corea 34
MA - Marocco 33
NL - Olanda 32
CZ - Repubblica Ceca 25
ES - Italia 25
IQ - Iraq 25
ZA - Sudafrica 24
UA - Ucraina 23
ID - Indonesia 22
PK - Pakistan 21
EE - Estonia 20
EC - Ecuador 18
GR - Grecia 17
VE - Venezuela 15
AZ - Azerbaigian 14
IR - Iran 14
SA - Arabia Saudita 14
UZ - Uzbekistan 14
LT - Lituania 13
CO - Colombia 12
AU - Australia 10
CL - Cile 10
IE - Irlanda 10
PH - Filippine 10
CH - Svizzera 8
BE - Belgio 7
CR - Costa Rica 7
EG - Egitto 7
HU - Ungheria 7
PE - Perù 7
PY - Paraguay 7
TW - Taiwan 7
AE - Emirati Arabi Uniti 6
IL - Israele 6
BO - Bolivia 5
HN - Honduras 5
JM - Giamaica 5
KE - Kenya 5
MG - Madagascar 5
MY - Malesia 5
NP - Nepal 5
PA - Panama 5
UY - Uruguay 5
AL - Albania 4
BH - Bahrain 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
JO - Giordania 4
LB - Libano 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
CY - Cipro 3
DK - Danimarca 3
KZ - Kazakistan 3
NG - Nigeria 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
DZ - Algeria 2
EU - Europa 2
GE - Georgia 2
LK - Sri Lanka 2
LV - Lettonia 2
MK - Macedonia 2
PS - Palestinian Territory 2
SV - El Salvador 2
A1 - Anonimo 1
AG - Antigua e Barbuda 1
AO - Angola 1
BN - Brunei Darussalam 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
Totale 16.428
Salva come PNG Salva come JPEG
Città #
Ashburn 969
Dallas 950
Singapore 783
Hong Kong 696
Chandler 571
Santa Clara 517
Fairfield 411
Shanghai 310
Milan 266
Houston 247
New York 242
Beijing 240
Woodbridge 223
Sofia 217
Vienna 215
Los Angeles 188
Munich 175
Seattle 174
Abidjan 163
Wilmington 148
Boardman 144
Cambridge 133
Princeton 127
Ann Arbor 126
Pisa 117
Florence 110
Lawrence 95
Frankfurt am Main 90
London 88
Boulder 82
Dakar 74
Rome 71
Serra 71
Medford 66
São Paulo 63
Ottawa 60
Istanbul 55
Redondo Beach 55
Tokyo 53
Buffalo 52
Ho Chi Minh City 51
Hefei 43
Dong Ket 42
Turku 42
Des Moines 39
Helsinki 38
Bremen 35
Redwood City 35
Hanoi 34
Dearborn 33
San Diego 32
Fuzhou 30
Denver 29
Montreal 29
Redmond 28
Warsaw 28
Nanjing 27
Belo Horizonte 26
Phoenix 26
Seoul 26
Düsseldorf 25
Nuremberg 23
Washington 23
Orem 22
Casablanca 21
Quanzhou 21
Atlanta 20
Boston 20
Brooklyn 20
Cascina 20
Guangzhou 19
Lucca 19
Toronto 19
Brno 18
Chicago 18
Ogden 18
Stockholm 18
Johannesburg 16
Lauterbourg 16
Vicopisano 16
Izmir 15
Paris 15
Poplar 15
Rio de Janeiro 15
Ankara 14
Bengaluru 14
Chengdu 14
Council Bluffs 14
Lancaster 14
Zhengzhou 14
Changsha 13
Hyderabad 13
Jiaxing 13
Mexico City 13
Mumbai 13
Tashkent 13
Brasília 12
Hangzhou 12
Scandicci 12
Amsterdam 11
Totale 10.771
Salva come PNG Salva come JPEG
Nome #
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 224
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 221
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 221
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
Targeted Therapy in Thyroid Cancer: State of the Art 210
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 206
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 206
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life 200
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 200
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 186
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 184
Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations 183
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 179
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 179
A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation 178
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 174
Il carcinoma tiroideo: nuove prospettive terapeutiche. 172
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 172
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 169
The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy 168
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 168
Potential impact of BMI on the aggressiveness of presentation and clinical outcome of Differentiated Thyroid Cancer 164
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 162
Central Neck Dissection Cannot Be Avoided In Medullary Thyroid Cancer (MTC) On The Basis Of Presurgical Serum Calcitonin (CT) 161
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 159
Role Of Prophylactic Central Compartment Lymph Node Dissection On The Outcome Of Patients With Papillary Thyroid Carcinoma And Synchronous Ipsilateral Cervical Lymph Node Metastases 158
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 158
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 157
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 154
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 152
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 152
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 151
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 151
Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma 151
Risk factors for renal calcifications and determinants of hypercalciuria in patients with chronic, post-surgical hypoparathyroidism 150
Efficacy and safety of long-term management of patients with chronic post-surgical hypoparathyroidism 148
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 148
Impact of energy-based devices in pediatric thyroid surgery 148
null 146
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 143
SAT-393 Cognitive Function Evaluation in an Italian Cohort of Patients with Post-Operative Hypoparathyroidism 142
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 141
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 140
Decreased serum vascular endothelial growth factor-D levels in metastatic patients with differentiated thyroid carcinoma 138
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 138
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 137
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 135
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 135
Increased Risk of Renal Complications in Patients with Chronic Postsurgical Hypoparathyroidism Treated with Conventional Therapy 134
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 134
Expression of duox1 in papillary thyroid cancer and in normal thyroid tissues and correlation with ret/ptc rearrangements 134
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 133
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 132
Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses 131
A Patient with Advanced Medullary Thyroid Cancer and Progressive Symptomatic Distant Metastases: When to Start Systemic Therapy 130
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 130
Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 130
Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center 130
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 129
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 128
Cabozantinib: An orphan drug for thyroid cancer 127
Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine 125
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 119
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 119
Predictors Of Vandetanib Response In The Locally Advanced Or Metastatic Medullary Thyroid Cancer: A Single Center Experience 118
Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes 114
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 114
After 20 Years, RET genetic screening still identifies new germline and somatic mutations 114
Prevalence and Risk Factors of Developing Fistula or Organ Perforation in Patients Treated with Lenvatinib for Radioiodine-Refractory Thyroid Cancer 114
RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency 112
Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series 111
Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance 110
Thyroid cancer and COVID-19: experience at one single thyroid disease referral center 110
Un caso di MEN2B con anomalie scheletriche multiple 109
Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer 109
Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone 108
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 108
null 107
First report of benign track seeding after robot-assisted transaxillary thyroid surgery 107
A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma 106
La scintigrafia con 99mTecnezio-metossi-isobutil-isonitrile è una metodica utile per caratterizzare il rischio di malignità nei noduli tiroidei a citologia indeterminata 106
Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response 103
Response to letter: "postoperative thyroglobulin and neck ultrasound in the risk restratification and decision to perform131i ablation" 103
Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer 103
Renal complications and quality of life in postsurgical hypoparathyroidism: a case–control study 103
Obesity as a risk factor for thyroid cancer 101
Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib 100
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 100
Management and follow-up of differentiated thyroid cancer not submitted to radioiodine treatment: a systematic review 99
MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients 98
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report 97
MicroRNA expression profiling of RAS-mutant thyroid tumors with follicular architecture: microRNA signatures to discriminate benign from malignant lesions 97
Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature 96
Ultrasound features and risk stratification systems to identify medullary thyroid carcinoma 94
Poorly differentiated and anaplastic thyroid cancer: Insights into genomics, microenvironment and new drugs 94
NF1 Gene Inactivation Acts as Tumor Driver in RET/RAS Negative Medullary Thyroid Carcinomas 93
Totale 14.099
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.198
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.198
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021481 0 0 0 0 0 88 78 43 60 40 63 109
2021/20221.061 35 32 29 52 208 142 47 42 56 50 74 294
2022/20232.211 239 320 191 166 208 229 44 162 453 17 157 25
2023/20241.476 108 143 199 118 191 273 87 35 26 23 109 164
2024/20254.567 56 157 68 274 480 449 360 216 473 551 463 1.020
2025/20263.980 493 901 789 676 712 409 0 0 0 0 0 0
Totale 16.769